What is Tesamorelin, and what does the research examine?

Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH 1-44), engineered to hold up in solution far longer than the native hormone. In the United States it turns up in research listings under a handful of names, including tesamorelin acetate and GHRH analog (1-44), but the compound is the same: the 44-residue GHRH sequence with a small chemical group added at one end to slow its breakdown. That single change is the whole point of the molecule, and it is why tesamorelin is a dependable bench tool for probing hypothalamic-pituitary communication and growth-hormone regulation.

Research use only. Tesamorelin is supplied strictly for in-vitro laboratory research. It is not for human or veterinary use, this research material has not been evaluated by the FDA, and this page does not describe dosing, administration or use in people or animals, and makes no therapeutic claims.

What tesamorelin is

Native GHRH is a hypothalamic peptide that signals the pituitary to make and release growth hormone. Its drawback as a research reagent is fragility: the intact hormone is cleaved rapidly at its N-terminus by dipeptidyl peptidase-4 (DPP-4) and cleared within minutes, which makes it awkward to work with in any system where you need a stable, defined exposure.

Tesamorelin solves that by adding a trans-3-hexenoic acid group to the N-terminus of the GHRH (1-44) sequence. The added group shields the vulnerable cleavage site, so the analog resists DPP-4 degradation and stays intact long enough to give reproducible results. Structurally it is still GHRH: the receptor-facing chemistry is unchanged, so it engages the same target as the native hormone. What changed is durability, not identity, and that is exactly the trade a research tool wants.

What the research actually examines

Tesamorelin binds and activates the GHRH receptor (GHRHR), a class B G-protein-coupled receptor carried by pituitary somatotrophs. Activation couples through Gs to adenylate cyclase, raising intracellular cAMP, which activates protein kinase A and CREB-mediated transcription of the growth-hormone gene. In cell-based and preclinical models this is the pathway under study, and experiments generally track:

• Receptor binding and selectivity at the GHRH receptor
• cAMP-dependent signaling, the immediate second-messenger readout of receptor activation
• Downstream transcriptional responses governing growth-hormone synthesis and secretion
• Stability and pharmacology of the analog relative to native GHRH, since resistance to degradation is its defining feature

As with any receptor agonist, the observed effects shift with concentration, exposure time and the model system, so the honest description of what tesamorelin does at the bench is that it characterizes GHRH-receptor signaling under defined conditions.

It is worth separating that from what gets claimed downstream. Search results for tesamorelin are heavy with body-composition and anti-aging language, most of it extrapolated from the growth-hormone axis rather than measured for the compound in the setting being described. The primary literature is receptor pharmacology and preclinical signaling work; the marketing narrative is a leap beyond it. Both can be discussed, but they are different things, and this page stays with the first.

How tesamorelin compares with other growth-hormone tools

Researchers rarely study the growth-hormone axis with a single reagent, which is why tesamorelin is often set beside its neighbors:

• CJC-1295 is also a GHRH analog, so it engages the same receptor. The CJC-1295 guide covers how the two are compared as GHRH-receptor tools.
• Ipamorelin works through a different receptor entirely, the ghrelin / growth-hormone secretagogue receptor (GHSR-1a), so pairing a GHRH analog with a secretagogue lets researchers probe two arms of growth-hormone regulation at once.
• MOTS-c sits in the adjacent metabolic-signaling literature rather than the GH axis, but shows up in the same workflows.

The reason to keep them straight is attribution: a GHRH-receptor result and a GHSR-1a result are not interchangeable, and a comparison only means something when each tool's target is clear.

Supply and format

We supply tesamorelin as a pre-mixed solution rather than a lyophilized powder, prepared under controlled conditions and verified by HPLC, with a batch-specific Certificate of Analysis that reports purity by HPLC and confirms identity by mass spectrometry for the exact lot you receive. Every compound is synthesized in our own UK laboratory rather than imported and repackaged, and each US batch is independently verified in a US laboratory before it ships. Recent certificates are in the COA library, and if you need to work out concentrations from the vial, the peptide calculator handles the arithmetic.

How it ships in the United States

For US laboratories tesamorelin is dispatched cold-chain from the warehouse that serves the United States, with tracked delivery across the country next business day. It is priced in US dollars and payable by Visa, Mastercard or Apple Pay. Because it ships as a solution, there is no powder to reconstitute and no bacteriostatic water to add; store it refrigerated at 2-8°C on arrival, not frozen.

What tesamorelin is not

• It is not an approved medicine in the form supplied here. This research material has not been evaluated by the FDA and is not for human or veterinary use.
• It is not native GHRH. The stabilizing modification is the whole reason it exists, so results obtained with tesamorelin should not be read as identical to native-hormone behavior without checking.
• It is not interchangeable with a growth-hormone secretagogue such as ipamorelin. They act at different receptors, and treating one result as the other confuses the mechanism.

Dosing and administration

We do not publish dosing, reconstitution-for-use or administration guidance for tesamorelin. The material is supplied strictly for in-vitro laboratory research and is not for human or veterinary use, so quantity guidance aimed at a person would be inconsistent with what is actually supplied. Experimental concentrations are specific to the model and endpoint and belong in the primary literature.

Related reading

• Compare it with another GHRH analog: what is CJC-1295?
• New to the topic? What are research peptides?